2023
DOI: 10.7759/cureus.33927
|View full text |Cite
|
Sign up to set email alerts
|

Review of Potential Barriers to Effective Hemostatic Management of Acquired Hemophilia A by Non-Hemophilia Experts in the United States

Abstract: Acquired hemophilia A (AHA) is an ultra-rare autoimmune disorder caused by autoantibodies against factor VIII. It often presents with life-threatening bleeding to non-hemophilia experts, who have limited awareness of this condition. This review evaluated hemostatic management and identified barriers to optimal management of AHA by non-hemophilia experts in the United States through a literature review. AHA case reports published by non-hemophilia experts from January 2016 through November 2021 in nonhematology… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 47 publications
0
2
0
Order By: Relevance
“…This was based on rpFVIII sharing sufficient sequence homology with hFVIII to be haemostatic but being different enough to be less susceptible to inactivation by circulating FVIII inhibitors. 21 In addition, these patients have a clear clinical need for rpFVIII as they are a difficult-to-treat group. In this surgery study, good haemostasis was achieved with rpFVIII during the immediate perioperative period, but 5 of the 8 patients experienced anamnestic reactions.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This was based on rpFVIII sharing sufficient sequence homology with hFVIII to be haemostatic but being different enough to be less susceptible to inactivation by circulating FVIII inhibitors. 21 In addition, these patients have a clear clinical need for rpFVIII as they are a difficult-to-treat group. In this surgery study, good haemostasis was achieved with rpFVIII during the immediate perioperative period, but 5 of the 8 patients experienced anamnestic reactions.…”
Section: Discussionmentioning
confidence: 99%
“…At the initiation of this study, it was expected that the benefit‐risk ratio would favour the short‐term use of rpFVIII in patients with CHAWI undergoing surgical or invasive procedures. This was based on rpFVIII sharing sufficient sequence homology with hFVIII to be haemostatic but being different enough to be less susceptible to inactivation by circulating FVIII inhibitors 21 . In addition, these patients have a clear clinical need for rpFVIII as they are a difficult‐to‐treat group.…”
Section: Discussionmentioning
confidence: 99%